Amendments to The Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-12. (Canceled)

- 13. (Currently amended) A method for activating a postsynaptic membrane of a cell, comprising contacting the cell with an effective amount of a biglycan therapeutic, such that the postsynaptic membrane is activated wherein the biglycan therapeutic activates muscle, skeletal, receptor tyrosine kinase (MuSK) on the cell, wherein the cell is situated in a human subject.
- 14. (Canceled)
- 15. (Original) The method of claim 13, wherein the biglycan therapeutic potentiates agrininduced phosphorylation of MuSK.
- 16. (Original) The method of claim 13, wherein the biglycan therapeutic upregulates utrophin levels.

17-31. (Canceled)

- 32. (Currently amended) The method of claim 13, wherein the biglycan therapeutic is a polypeptide including a biglycan amino acid sequence which is at least about 90% identical to SEQ ID NO: No. 9, or a portion thereof.
- 33. (Previously presented) The method of claim 32, wherein the biglycan therapeutic binds to MuSK.
- 34. (Previously presented) The method of claim 32, wherein the biglycan amino acid sequence includes one or more Leucine Rich Repeats (LRRs) of human biglycan having SEQ ID NO: 9.
- 35. (Previously presented) The method of claim 32, wherein the polypeptide is derivatized with one or more glycosaminoglycan (GAG) side chains.
- 36. (Previously presented) The method of claim 32, wherein the biglycan amino acid sequence is at least about 90% identical to amino acids 38-365 of SEO ID NO: 9.
- 37. (Previously presented) The method of claim 32, wherein the biglycan amino acid sequence is at least about 95% identical to amino acids 38-365 of SEQ ID NO: 9. 9608161

- 38. (Previously presented) The method of claim 32, wherein the cell is a muscle cell.
- 39. (New) A method for activating a postsynaptic membrane of a cell in vitro or ex vivo, comprising:
 - i) contacting the cell with an effective amount of a biglycan therapeutic; and
 - ii) assaying activity of muscle, skeletal, receptor tyrosine kinase (MuSK), wherein elevated activity of MuSK indicates activation of the postsynaptic membrane of the cell.